‘Big Night Out’ Gone Bad: US FDA Says Instagram Post For Merz’s Xeomin Minimizes Risks, Overstates Efficacy

 
• By Sue Sutter
  
Xeomin Instagram post
The FDA's Office of Prescription Drug Promotion found lots to object to in Nate Berkus' Instagram post for Merz Pharma's Xeomin. (Screenshot)

More from Marketing & Advertising

More from Compliance